LAVA Therapeutics Gears Up for the H.C. Wainwright Conference 2024
UTRECHT, The Netherlands and PHILADELPHIA – LAVA Therapeutics N.V. (NASDAQ: LVTX), an innovative clinical-stage immuno-oncology company, is thrilled to announce its participation in the upcoming H.C. Wainwright 26th Annual Global Investment Conference. This event is an excellent opportunity to showcase ongoing medical advancements and explore investment possibilities.
Details of the Presentation
Stephen Hurly, the Chief Executive Officer of LAVA Therapeutics, will present in a fireside chat format. This engaging session is set for Monday at 3:30 PM ET, providing attendees with valuable insights into the company’s innovative strategies and future plans. The presentation will be available for viewing on the company’s investor relations webpage.
For those unable to attend live, a replay of the presentation will be accessible for up to 90 days after the event. The company encourages everyone to check their investor relations section for updates and information on upcoming events.
About LAVA Therapeutics and Their Innovations
LAVA Therapeutics N.V. is committed to revolutionizing cancer treatment through its unique Gammabody platform, which focuses on bispecific gamma-delta T cell engagers. These groundbreaking therapies aim to specifically target and eliminate various solid tumors and hematologic cancers.
Current Clinical Research Initiatives
At present, LAVA is actively seeking participants for a Phase 1 dose escalation study (NCT05369000) to assess LAVA-1207. This significant initiative targets patients with metastatic castration-resistant prostate cancer (mCRPC) and evaluates both monotherapy and combination treatments with interleukin-2 (IL-2). Additionally, there is exciting news about the expansion of this Phase 1 study to include a combination approach with KEYTRUDA® (pembrolizumab) in collaboration with Merck & Co., Inc.
Strategic Partnerships and Licensing Agreements
LAVA has made impressive progress in its business endeavors. The company has established a licensing agreement for PF-08046052 (formerly known as LAVA-1223) with Pfizer Inc., aimed at advancing clinical development and commercialization. This partnership, along with several pre-clinical programs, highlights LAVA's dedication to advancing immune-oncology therapies.
Advancing Cancer Care
The Gammabody platform represents a significant innovation, designed to leverage the specific immune response of gamma-delta T cells against tumors. By effectively engaging these immune cells, the goal is to offer patients more targeted and effective therapies.
Frequently Asked Questions
What is the focus of LAVA Therapeutics?
LAVA Therapeutics is focused on developing immuno-oncology therapies, particularly through their Gammabody platform, which features bispecific gamma-delta T cell engagers.
When is the H.C. Wainwright Conference?
The 26th Annual Global Investment Conference is set for Monday, with Stephen Hurly's presentation scheduled for 3:30 PM ET.
Where can I watch the presentation?
The presentation will be accessible on the investor relations section of the LAVA Therapeutics website.
What is the company’s lead program?
LAVA's lead program is LAVA-1207, which is currently undergoing a Phase 1 clinical trial targeting metastatic castration-resistant prostate cancer.
Who can provide more information about LAVA Therapeutics?
For additional inquiries, interested individuals can reach out to Investor Relations at ir@lavatherapeutics.com.
